03:29:19 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



Ventripoint Diagnostics Ltd (2)
Symbol VPT
Shares Issued 156,823,905
Close 2023-08-21 C$ 0.265
Market Cap C$ 41,558,335
Recent Sedar Documents

Ventripoint sells VMS+ to English children's hospital

2023-08-22 12:06 ET - News Release

An anonymous director reports

VENTRIPOINT WELCOMES EVELINA LONDON CHILDREN'S HOSPITAL AS NEWEST VMS+ USER

Evelina London Children's Hospital (part of Guy's and St Thomas' NHS Foundation Trust) is the newest user to adopt Ventripoint Diagnostics Ltd.'s VMS+ 3.0 system upgrade.

Dr. Saleha Kabir, lead physiologist in pediatrics and advanced echocardiography, stated: "Having had experience with the older Ventripoint system, the new VMS+ system with its increased functionality is a great addition to our echo lab. The more compact console increases accessibility and mobility, which allows us to use it in a variety of settings, and the simplified workflow makes image acquisition faster, which is fantastic for our small and easily distracted pediatric patients!"

Evelina London Children's Hospital is a specialist NHS hospital in London, England, and is the second-largest provider of children's services in London caring for children and young people from across south London and southeast England. Evalina London has a range of children's heart clinics, including the fetal cardiology clinic and arrhythmia clinic. The children's heart services (cardiology) cares for around 6,000 patients each year with all kinds of children's heart problems including:

  • Those present from birth, known as congenital heart disease;
  • Those that develop after birth, known as acquired heart disease;
  • Rhythm disturbances.

The VMS+ 3.0 system will provide the pediatric cardiology team with a way to obtain accurate volumes of all four chambers of the heart. The VMS+ uses standard 2-D echo to obtain the necessary metrics with the accuracy of a cardiac MRI (magnetic resonanceimaging). The VMS+ will support Evelina London's patient load and have a positive impact in patient care.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.